risperidone has been researched along with Overweight in 9 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to characterize weight changes in schizophrenia patients taking risperidone as part of a randomized, controlled, open-label clinical trial." | 9.15 | Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia. ( Bo, QJ; Chiu, HF; Dixon, LB; Kreyenbuhl, JA; Lai, KY; Lee, EH; Ungvari, GS; Wang, CY; Xiang, YT, 2011) |
| "Weight gain and metabolic disturbances, such as dyslipidemia and hyperglycaemia, are common side effects of most antipsychotic drugs, including risperidone." | 7.77 | Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver. ( Bordet, R; Bouchaert, E; Cussac, D; Duriez, P; Helleboid, A; Hum, D; Lauressergues, E; Luc, G; Majd, Z; Martin, F; Staels, B, 2011) |
| "This study aimed to characterize weight changes in schizophrenia patients taking risperidone as part of a randomized, controlled, open-label clinical trial." | 5.15 | Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia. ( Bo, QJ; Chiu, HF; Dixon, LB; Kreyenbuhl, JA; Lai, KY; Lee, EH; Ungvari, GS; Wang, CY; Xiang, YT, 2011) |
| "Children treated with risperidone or quetiapine are at a significant risk for developing obesity, elevated waist circumference, and dyslipidemia during 12 months of treatment." | 3.81 | Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. ( Davidson, J; Nguyen, D; Panagiotopoulos, C; Ronsley, R, 2015) |
| "Weight gain and metabolic disturbances, such as dyslipidemia and hyperglycaemia, are common side effects of most antipsychotic drugs, including risperidone." | 3.77 | Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver. ( Bordet, R; Bouchaert, E; Cussac, D; Duriez, P; Helleboid, A; Hum, D; Lauressergues, E; Luc, G; Majd, Z; Martin, F; Staels, B, 2011) |
| "A sample included 61 patients, 53 men and 8 women, with ICD-10 episodic schizophrenia in the remission after treatment with atypical neuroleptics (risperidon, olanzapine, clozapine)." | 3.74 | [Prescription of traditional neuroleptics in the remission period for schizophrenic patients with excess of body mass caused by atypical antipsychotics]. ( Danilov, DS; Tiul'pin, IuG, 2007) |
| " Role of ghrelin (RIA), resistin and TNF-alpha (ELISA) in weight gain and insulin resistance (fasting plasma insulin, HOMA, ELISA) was studied in Hungarian psychiatryic patients (n=60) treated with SGA (clozapine, olanzapine, risperidone, quetiapine, 15 each)." | 3.73 | [Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics]. ( Birkás Kováts, D; Cseh, K; Faludi, G; Palik, E, 2005) |
| "Patients with schizophrenia have an increased prevalence of metabolic disturbances compared with the general population." | 1.48 | High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey. ( Matsuda, H; Mori, T; Okamoto, K; Ono, S; Ozeki, Y; Sagae, T; Shimoda, K; Someya, T; Sugai, T; Sugawara, N; Suzuki, Y; Yamazaki, M; Yasui-Furukori, N, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ono, S | 1 |
| Sugai, T | 1 |
| Suzuki, Y | 1 |
| Yamazaki, M | 1 |
| Shimoda, K | 1 |
| Mori, T | 1 |
| Ozeki, Y | 1 |
| Matsuda, H | 1 |
| Sugawara, N | 1 |
| Yasui-Furukori, N | 1 |
| Okamoto, K | 1 |
| Sagae, T | 1 |
| Someya, T | 1 |
| Ronsley, R | 1 |
| Nguyen, D | 1 |
| Davidson, J | 1 |
| Panagiotopoulos, C | 1 |
| Bond, DJ | 1 |
| Kauer-Sant'Anna, M | 1 |
| Lam, RW | 1 |
| Yatham, LN | 1 |
| Lauressergues, E | 1 |
| Martin, F | 1 |
| Helleboid, A | 1 |
| Bouchaert, E | 1 |
| Cussac, D | 1 |
| Bordet, R | 1 |
| Hum, D | 1 |
| Luc, G | 1 |
| Majd, Z | 1 |
| Staels, B | 1 |
| Duriez, P | 1 |
| Xiang, YT | 1 |
| Wang, CY | 1 |
| Ungvari, GS | 1 |
| Kreyenbuhl, JA | 1 |
| Chiu, HF | 1 |
| Lai, KY | 1 |
| Lee, EH | 1 |
| Bo, QJ | 1 |
| Dixon, LB | 1 |
| Birkás Kováts, D | 1 |
| Palik, E | 1 |
| Faludi, G | 1 |
| Cseh, K | 1 |
| Neovius, M | 1 |
| Eberhard, J | 1 |
| Lindström, E | 1 |
| Levander, S | 1 |
| Danilov, DS | 1 |
| Tiul'pin, IuG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326] | 120 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for risperidone and Overweight
| Article | Year |
|---|---|
Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Body Weight; Brief Psychiatric Rating Scale; China; Di | 2011 |
8 other studies available for risperidone and Overweight
| Article | Year |
|---|---|
High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Body Mass Index; Cholesterol, HDL; Correlation of D | 2018 |
Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study.
Topics: Adolescent; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disor | 2015 |
Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Bod | 2010 |
Second-generation antipsychotics cause weight gain in youths.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Dibenzothi | 2010 |
Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver.
Topics: Animals; Antipsychotic Agents; Cells, Cultured; Disease Models, Animal; Fatty Acid Synthases; Female | 2011 |
[Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics].
Topics: Antipsychotic Agents; Benzodiazepines; Carbohydrate Metabolism; Case-Control Studies; Clozapine; Dib | 2005 |
Weight development in patients treated with risperidone: a 5-year naturalistic study.
Topics: Adult; Aged; Antipsychotic Agents; Body Weight; Female; Follow-Up Studies; Humans; Male; Middle Aged | 2007 |
[Prescription of traditional neuroleptics in the remission period for schizophrenic patients with excess of body mass caused by atypical antipsychotics].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Drug Prescriptions; Female | 2007 |